[Aspirin against cylindromatosis? Molecular functions of the CYLD tumor suppressor].
Funk
J O
JO
Oncology Research Darmstadt, Global Preclinical R&D, Merck KGaA. Jens-Oliver.Funk@merck.de
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D001241:Aspirin / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000235:genetics*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics; D004252:DNA Mutational Analysis; D000074749:Deubiquitinating Enzyme CYLD; D016147:Genes, Tumor Suppressor; D006258:Head and Neck Neoplasms / Q000235:genetics*; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D012878:Skin Neoplasms / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000235:genetics*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016328:NF-kappa B; D025521:Tumor Suppressor Proteins; C409984:CYLD protein, human; D000074749:Deubiquitinating Enzyme CYLD; D001241:Aspirin